Last reviewed · How we verify

NCT04380766: PanCOVID

Covid-19 Pandemic and Pancreatic Surgery in Italy

Completed Last updated 3 August 2020
What this trial tests

trial testing Evaluation of changes in the diagnostic-therapeutic pathway for patients affected by pancreatic cancer in Pancreatic Cancer in 730 participants. Completed in 31 July 2020.

Timeline
1 January 2019
Primary endpoint
31 July 2020
31 July 2020

Quick facts

Lead sponsorFondazione Policlinico Universitario Agostino Gemelli IRCCS
StatusCompleted
Study typeOBSERVATIONAL
Enrollment730
Start date1 January 2019
Primary completion31 July 2020
Estimated completion31 July 2020
Sites1 location across Italy

Drugs / interventions tested

Conditions studied

Sponsor

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Who can join

18 and older, any sex, with Pancreatic Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Pancreatic cancer (PC) is recognized as one of the most challenging tumors to deal with and it is still characterized by a poor long-term prognosis. However, treatment of PC in high-volume centers with the support of a multidisciplinary approach has widely demonstrated improvement both in terms of short- and long-term outcomes. The recent worldwide spread of Covid-19 pandemic significantly affected the healthcare systems of most countries in the world, particularly in red areas such as Italy, with more than 100.000 cases in a two-month time lapse. This inevitably reflected in a reorganization of hospital activities, including the diagnostic and therapeutic pathways for PC treatment. With the aim of giving an objective and real representation of the impact of Covid-19 on PC treatment, the investigator here propose a multicenter Italian observational study comparing a 6-month period before and during the Covid-19 pandemic. Only high-volume centers will be involved in the study. A comparison between the general, clinical, endoscopic and surgical outcomes will be performed by means of a global and month-by-month analysis between the two study periods.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

  1. Cancer Management during COVID-19 Pandemic: Is Immune Checkpoint Inhibitors-Based Immunotherapy Harmful or Beneficial?
    Vivarelli S, Falzone L, Grillo CM, Scandurra G, et al · · 2020 · cited 63× · PMID 32785162 · DOI 10.3390/cancers12082237
  2. Quantitative assessment of the impact of COVID-19 pandemic on pancreatic surgery: an Italian multicenter analysis of 1423 cases from 10 tertiary referral centers.
    Quero G, Pecorelli N, Paiella S, Fiorillo C, et al · · 2022 · cited 8× · PMID 34817837 · DOI 10.1007/s13304-021-01171-8

Verify or expand the search:

Other recruiting trials for Pancreatic Cancer

Currently open trials in the same condition.

Other Fondazione Policlinico Universitario Agostino Gemelli IRCCS trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04380766.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing